Attached files
file | filename |
---|---|
EX-32 - EX-32 - CTI BIOPHARMA CORP | ctic-ex32_7.htm |
EX-15 - EX-15 - CTI BIOPHARMA CORP | ctic-ex15_8.htm |
EX-31.2 - EX-31.2 - CTI BIOPHARMA CORP | ctic-ex312_9.htm |
EX-31.1 - EX-31.1 - CTI BIOPHARMA CORP | ctic-ex311_6.htm |
EX-10.3 - EX-10.3 - CTI BIOPHARMA CORP | ctic-ex103_233.htm |
EX-10.1 - EX-10.1 - CTI BIOPHARMA CORP | ctic-ex101_334.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
x |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended: June 30, 2015
OR
¨ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number 001-12465
CTI BIOPHARMA CORP.
(Exact name of registrant as specified in its charter)
Washington |
|
91-1533912 |
(State or other jurisdiction of |
|
(I.R.S. Employer |
|
|
|
3101 Western Avenue, Suite 600 |
|
|
Seattle, Washington |
|
98121 |
(Address of principal executive offices) |
|
(Zip Code) |
(206) 282-7100
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer |
|
¨ |
|
Accelerated filer |
|
x |
|
|
|
|
|||
Non-accelerated filer |
|
¨ (Do not check if a smaller reporting company) |
|
Smaller reporting company |
|
¨ |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:
Class |
|
Outstanding at July 30, 2015 |
Common Stock, no par value |
|
180,659,075 |
TABLE OF CONTENTS
2
PART 1 – FINANCIAL INFORMATION
CTI BIOPHARMA CORP.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share amounts)
June 30, |
|
|
December 31, |
|
|||
|
2015 |
|
|
2014 |
|
||
|
(unaudited) |
|
|
|
|
|
|
ASSETS |
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
Cash and cash equivalents |
$ |
54,864 |
|
|
$ |
70,933 |
|
Accounts receivable, net |
|
880 |
|
|
|
2,011 |
|
Inventory |
|
3,607 |
|
|
|
4,182 |
|
Prepaid expenses and other current assets |
|
4,512 |
|
|
|
3,379 |
|
Total current assets |
|
63,863 |
|
|
|
80,505 |
|
Property and equipment, net |
|
4,148 |
|
|
|
4,646 |
|
Other assets |
|
5,447 |
|
|
|
7,136 |
|
Total assets |
$ |
73,458 |
|
|
$ |
92,287 |
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS' EQUITY |
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
Accounts payable |
$ |
11,180 |
|
|
$ |
6,356 |
|
Accrued expenses |
|
17,440 |
|
|
|
19,734 |
|
Warrant liability |
|
368 |
|
|
|
— |
|
Current portion of deferred revenue |
|
847 |
|
|
|
826 |
|
Current portion of long-term debt |
|
2,824 |
|
|
|
9,014 |
|
Other current liabilities |
|
438 |
|
|
|
410 |
|
Total current liabilities |
|
33,097 |
|
|
|
36,340 |
|
Deferred revenue, less current portion |
|
1,430 |
|
|
|
1,779 |
|
Long-term debt, less current portion |
|
48,800 |
|
|
|
8,363 |
|
Other liabilities |
|
5,659 |
|
|
|
5,882 |
|
Total liabilities |
|
88,986 |
|
|
|
52,364 |
|
Commitments and contingencies |
|
|
|
|
|
|
|
Common stock purchase warrants |
|
— |
|
|
|
1,445 |
|
Shareholders' equity (deficit): |
|
|
|
|
|
|
|
Common stock, no par value: |
|
|
|
|
|
|
|
Authorized shares - 315,000,000 and 215,000,000 at June 30, 2015 and December 31, 2014, respectively |
|
|
|
|
|
|
|
Issued and outstanding shares - 180,372,288 and 176,761,099 at June 30, 2015 and December 31, 2014, respectively |
|
2,031,982 |
|
|
|
2,023,949 |
|
Accumulated other comprehensive loss |
|
(6,886 |
) |
|
|
(6,499 |
) |
Accumulated deficit |
|
(2,036,888 |
) |
|
|
(1,975,695 |
) |
Total CTI shareholders' equity (deficit) |
|
(11,792 |
) |
|
|
41,755 |
|
Noncontrolling interest |
|
(3,736 |
) |
|
|
(3,277 |
) |
Total shareholders' equity (deficit) |
|
(15,528 |
) |
|
|
38,478 |
|
Total liabilities and shareholders' equity |
$ |
73,458 |
|
|
$ |
92,287 |
|
See accompanying notes.
3
CTI BIOPHARMA CORP.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(unaudited)
Three Months Ended |
|
|
Six Months Ended |
|
|||||||||||
|
June 30, |
|
|
June 30, |
|
||||||||||
|
2015 |
|
|
2014 |
|
|
2015 |
|
|
2014 |
|
||||
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product sales, net |
$ |
849 |
|
|
$ |
1,148 |
|
|
$ |
1,654 |
|
|
$ |
2,416 |
|
License and contract revenue |
|
251 |
|
|
|
195 |
|
|
|
2,174 |
|
|
|
338 |
|
Total revenues |
|
1,100 |
|
|
|
1,343 |
|
|
|
3,828 |
|
|
|
2,754 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating costs and expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of product sold |
|
183 |
|
|
|
202 |
|
|
|
373 |
|
|
|
347 |
|
Research and development |
|
19,320 |
|
|
|
14,017 |
|
|
|
36,791 |
|
|
|
26,196 |
|
Selling, general and administrative |
|
12,624 |
|
|
|
13,792 |
|
|
|
24,921 |
|
|
|
30,542 |
|
Other operating expense |
|
— |
|
|
|
— |
|
|
|
253 |
|
|
|
— |
|
Total operating costs and expenses |
|
32,127 |
|
|
|
28,011 |
|
|
|
62,338 |
|
|
|
57,085 |
|
Loss from operations |
|
(31,027 |
) |
|
|
(26,668 |
) |
|
|
(58,510 |
) |
|
|
(54,331 |
) |
Non-operating income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
(597 |
) |
|
|
(467 |
) |
|
|
(1,091 |
) |
|
|
(931 |
) |
Amortization of debt discount and issuance costs |
|
(131 |
) |
|
|
(185 |
) |
|
|
(311 |
) |
|
|
(363 |
) |
Foreign exchange gain (loss) |
|
185 |
|
|
|
(160 |
) |
|
|
(543 |
) |
|
|
(165 |
) |
Other non-operating income (expense) |
|
(1,196 |
) |
|
|
1 |
|
|
|
(1,196 |
) |
|
|
(885 |
) |
Total non-operating expense, net |
|
(1,739 |
) |
|
|
(811 |
) |
|
|
(3,141 |
) |
|
|
(2,344 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss before noncontrolling interest |
|
(32,766 |
) |
|
|
(27,479 |
) |
|
|
(61,651 |
) |
|
|
(56,675 |
) |
Noncontrolling interest |
|
170 |
|
|
|
80 |
|
|
|
458 |
|
|
|
274 |
|
Net loss |
$ |
(32,596 |
) |
|
$ |
(27,399 |
) |
|
$ |
(61,193 |
) |
|
$ |
(56,401 |
) |
Basic and diluted net loss per common share |
$ |
(0.19 |
) |
|
$ |
(0.19 |
) |
|
$ |
(0.35 |
) |
|
$ |
(0.39 |
) |
Shares used in calculation of basic and diluted net loss per common share |
|
175,458 |
|
|
|
144,453 |
|
|
|
174,706 |
|
|
|
143,302 |
|
See accompanying notes.
4
CTI BIOPHARMA CORP.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(In thousands)
(unaudited)
Three Months Ended |
|
|
Six Months Ended |
|
|||||||||||
|
June 30, |
|
|
June 30, |
|
||||||||||
|
2015 |
|
|
2014 |
|
|
2015 |
|
|
2014 |
|
||||
Net loss before noncontrolling interest |
$ |
(32,766 |
) |
|
$ |
(27,479 |
) |
|
$ |
(61,651 |
) |
|
$ |
(56,675 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income (loss): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustments |
|
(752 |
) |
|
|
76 |
|
|
|
1,495 |
|
|
|
47 |
|
Unrealized foreign exchange gain (loss) on intercompany balance |
|
880 |
|
|
|
— |
|
|
|
(1,874 |
) |
|
|
— |
|
Net unrealized loss on securities available-for-sale: |
|
(13 |
) |
|
|
(66 |
) |
|
|
(8 |
) |
|
|
(58 |
) |
Other comprehensive income (loss) |
|
115 |
|
|
|
10 |
|
|
|
(387 |
) |
|
|
(11 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive loss |
|
(32,651 |
) |
|
|
(27,469 |
) |
|
|
(62,038 |
) |
|
|
(56,686 |
) |
Comprehensive loss attributable to noncontrolling interest |
|
170 |
|
|
|
80 |
|
|
|
458 |
|
|
|
274 |
|
Comprehensive loss attributable to CTI |
$ |
(32,481 |
) |
|
$ |
(27,389 |
) |
|
$ |
(61,580 |
) |
|
$ |
(56,412 |
) |
See accompanying notes.
5
CTI BIOPHARMA CORP.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(unaudited)
|
Six Months Ended June 30, |
|
|||||
|
2015 |
|
|
2014 |
|
||
Operating activities |
|
|
|
|
|
|
|
Net loss |
$ |
(61,651 |
) |
|
$ |
(56,675 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
Share-based compensation expense |
|
7,109 |
|
|
|
13,185 |
|
Depreciation and amortization |
|
512 |
|
|
|
616 |
|
Loss on debt extinguishment |
|
1,211 |
|
|
|
— |
|
Noncash interest expense |
|
311 |
|
|
|
363 |
|
Change in value of warrant liability |
|
(15 |
) |
|
|
886 |
|
Other |
|
(195 |
) |
|
|
409 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
Accounts receivable |
|
973 |
|
|
|
(380 |
) |
Inventory |
|
245 |
|
|
|
22 |
|
Prepaid expenses and other current assets |
|
(1,192 |
) |
|
|
73 |
|
Other assets |
|
1,198 |
|
|
|
(366 |
) |
Accounts payable |
|
4,976 |
|
|
|
1,346 |
|
Accrued expenses and other |
|
(2,082 |
) |
|
|
2,450 |
|
Deferred revenue |
|
(328 |
) |
|
|
(338 |
) |
Total adjustments |
|
12,723 |
|
|
|
18,266 |
|
Net cash used in operating activities |
|
(48,928 |
) |
|
|
(38,409 |
) |
|
|
|
|
|
|
|
|
Investing activities |
|
|
|
|
|
|
|
Purchases of property and equipment |
|
(24 |
) |
|
|
(58 |
) |
Net cash used in investing activities |
|
(24 |
) |
|
|
(58 |
) |
|
|
|
|
|
|
|
|
Financing activities |
|
|
|
|
|
|
|
Proceeds from Hercules debt, net of issuance costs |
|
5,910 |
|
|
|
(73 |
) |
Repayment of Hercules debt |
|
(4,659 |
) |
|
|
— |
|
Proceeds from Baxalta milestone advance |
|
32,000 |
|
|
|
— |
|
Payment of tax withholding obligations related to stock compensation |
|
(544 |
) |
|
|
(108 |
) |
Cash paid for Series 21 preferred stock issuance costs |
|
(227 |
) |
|
|
— |
|
Other |
|
22 |
|
|
|
59 |
|
Net cash provided by (used in) financing activities |
|
32,502 |
|
|
|
(122 |
) |
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents |
|
381 |
|
|
|
134 |
|
|
|
|
|
|
|
|
|
Net decrease in cash and cash equivalents |
|
(16,069 |
) |
|
|
(38,455 |
) |
Cash and cash equivalents at beginning of period |
|
70,933 |
|
|
|
71,639 |
|
Cash and cash equivalents at end of period |
$ |
54,864 |
|
|
$ |
33,184 |
|
|
|
|
|
|
|
|
|
Supplemental disclosure of cash flow information |
|
|
|
|
|
|
|
Cash paid during the period for interest |
$ |
960 |
|
|
$ |
911 |
|
Cash paid during the period for taxes |
$ |
— |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
Supplemental disclosure of noncash financing and investing activities |
|
|
|
|
|
|
|
Issuance of common stock upon exercise of common stock purchase warrants |
$ |
— |
|
|
$ |
1,877 |
|
Repayment and issuance of Hercules debt |
$ |
13,815 |
|
|
$ |
— |
|
See accompanying notes.
6
CTI BIOPHARMA CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
1. |
Description of Business and Summary of Significant Accounting Policies |
CTI BioPharma Corp., together with its wholly-owned subsidiaries, also referred to collectively in this Quarterly Report on Form 10-Q as CTI, the Company, we, us or our, is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and health care providers. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners. We are currently concentrating our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are primarily focused on commercializing PIXUVRI ® (pixantrone), or PIXUVRI, in the European Union, or the E.U., for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma and conducting a Phase 3 clinical trial program evaluating pacritinib for the treatment of adult patients with myelofibrosis to support regulatory submission for approval in the United States, or the U.S., and Europe. We are also evaluating pacritinib in earlier clinical trials as treatment for other blood-related cancers.
We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration in the U.S., the European Medicines Agency, or the EMA, in the E.U. and comparable agencies in other countries. Obtaining approval for a new therapeutic product is never certain, may take many years and may involve expenditure of substantial resources.
Basis of Presentation
The accompanying unaudited financial information of CTI as of June 30, 2015 and for the three and six months ended June 30, 2015 and 2014 has been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and with the instructions to Quarterly Report on Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, such financial information includes all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial position at such date and the operating results and cash flows for such periods. Operating results for the three and six months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the entire year or for any other subsequent interim period.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to the rules of the U.S. Securities and Exchange Commission, or the SEC. These unaudited financial statements and related notes should be read in conjunction with our audited annual financial statements for the year ended December 31, 2014 included in our Annual Report on Form 10-K filed with the SEC on March 12, 2015.
The condensed consolidated balance sheet at December 31, 2014 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by generally accepted accounting principles in the U.S. for complete financial statements.
Principles of Consolidation
The accompanying condensed consolidated financial statements include the accounts of CTI and its wholly-owned subsidiaries, which include Systems Medicine LLC and CTI Life Sciences Limited, or CTILS. We also retain ownership of our branch, CTI BioPharma Corp.– Sede Secondaria, or CTI (Europe); however, we ceased operations related to this branch in September 2009. In addition, CTI Commercial LLC, a wholly-owned subsidiary, was included in the consolidated financial statements until dissolution in March 2012.
As of June 30, 2015, we also had a 61% interest in our majority-owned subsidiary, Aequus Biopharma, Inc., or Aequus. The remaining interest in Aequus not held by CTI is reported as noncontrolling interest in the consolidated financial statements.
All intercompany transactions and balances are eliminated in consolidation.
7
Accounts Receivable
Our accounts receivable balance includes trade receivables related to PIXUVRI sales. We estimate an allowance for doubtful accounts based upon the age of outstanding receivables and our historical experience of collections, which includes adjustments for risk of loss for specific customer accounts. We periodically review the estimation process and make changes to our assumptions as necessary. When it is deemed probable that a customer account is uncollectible, the account balance is written off against the existing allowance. We also consider the customers’ country of origin to determine if an allowance is required. We continue to monitor economic conditions, including the volatility associated with international economies, the sovereign debt crisis in certain European countries and associated impacts on the financial markets and our business. As of June 30, 2015 and December 31, 2014, our accounts receivable did not include any balance from a customer in a country that has exhibited financial stress that would have had a material impact on our financial results. Our allowance for doubtful accounts balance was $0.3 million as of June 30, 2015 and $0.1 million as of December 31, 2014.
Liquidity
The accompanying condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date of these condensed consolidated financial statements. However, we have incurred net losses since inception and expect to generate losses for the next few years primarily due to research and development costs for pacritinib, PIXUVRI, tosedostat and Opaxio.
Our available cash and cash equivalents were $54.9 million as of June 30, 2015. We believe that our present financial resources, together with milestone payments projected to be received under certain of our contractual agreements and our ability to control costs and expected net sales of PIXUVRI, will only be sufficient to fund our operations through the fourth quarter of 2015. This raises substantial doubt about our ability to continue as a going concern.
Accordingly, we will need to raise additional funds to operate our business. We may seek to raise such capital through public or private equity financings, partnerships, collaborations, joint ventures, disposition of assets, debt financings or restructurings, bank borrowings or other sources of financing. However, we have a limited number of authorized shares of common stock available for issuance and additional funding may not be available on favorable terms or at all. If additional funds are raised by issuing equity securities, substantial dilution to existing shareholders may result. If we fail to obtain additional capital when needed, our ability to operate as a going concern will be harmed, and we may be required to delay, scale back or eliminate some or all of our research and development programs, reduce our selling, general and administrative expenses, be unable to attract and retain highly qualified personnel, refrain from making our contractually required payments when due (including debt payments) and/or may be forced to cease operations, liquidate our assets and possibly seek bankruptcy protection. The accompanying condensed consolidated financial statements do not include any adjustments that may result from the outcome of this uncertainty.
Value Added Tax Receivable
Our European operations are subject to a value added tax, or VAT, which is usually applied to all goods and services purchased and sold throughout Europe. The VAT receivable is approximately $4.7 million and $4.9 million as of June 30, 2015 and December 31, 2014, of which $4.4 million and $4.7 million is included in other assets and $0.3 million and $0.2 million is included in prepaid expenses and other current assets as of June 30, 2015 and December 31, 2014, respectively. The collection period of VAT receivable for our European operations ranges from approximately three months to five years. For our Italian VAT receivable, the collection period is approximately three to five years. As of June 30, 2015, the VAT receivable related to operations in Italy is approximately $4.4 million. We review our VAT receivable balance for impairment whenever events or changes in circumstances indicate the carrying amount might not be recoverable.
Inventory
We carry inventory at the lower of cost or market. The cost of finished goods and work in process is determined using the standard-cost method, which approximates actual cost based on a first-in, first-out method. Inventory includes the cost of materials, third-party contract manufacturing and overhead costs, quality control costs and shipping costs from the manufacturers to the final distribution warehouse associated with the production and distribution of PIXUVRI. Production costs for our other product candidates continue to be charged to research and development expense as incurred prior to regulatory approval or until our estimate for regulatory approval becomes probable. We review our inventories on a quarterly basis for impairment and reserves are established when necessary. Estimates of excess inventory consider our projected sales of the product and the remaining shelf lives of product. In the event we identify excess, obsolete or unsalable inventory, the value is written down to the net realizable value. Based on assessment of shelf lives and net realizable value of the product, $1,000 reserve for excess, obsolete or unsalable inventory was recorded as of June 30, 2015. No reserve was recorded as of June 30, 2014.
8
Revenue Recognition
We currently have conditional marketing authorization for PIXUVRI in the E.U. Revenue is recognized when there is persuasive evidence of the existence of an agreement, delivery has occurred, prices are fixed or determinable, and collectability is assured. Where the revenue recognition criteria are not met, we defer the recognition of revenue by recording deferred revenue until such time that all criteria under the provision are met.
Product sales
We sell PIXUVRI through a limited number of distributors and directly to health care providers in Austria, Denmark, Finland, Germany, Norway, Sweden and the United Kingdom, or the U.K. We generally record product sales upon receipt of the product by the health care providers and certain distributors at which time title and risk of loss pass. Product sales are recorded net of distributor discounts, estimated government-mandated rebates, trade discounts, and estimated product returns. Reserves are established for these deductions and actual amounts incurred are offset against the applicable reserves. We reflect these reserves as either a reduction in the related account receivable or as an accrued liability depending on the nature of the sales deduction. These estimates are periodically reviewed and adjusted as necessary.
Government-mandated discounts and rebates
Our products are subject to certain programs with government entities in the E.U. whereby pricing on products is discounted below distributor list price to participating health care providers. These discounts are provided to participating health care providers either at the time of sale or through a claim by the participating health care providers for a rebate. Due to estimates and assumptions inherent in determining the amount of government-mandated discounts and rebates, the actual amount of future claims may be different from our estimates, at which time we would adjust our reserves accordingly.
Product returns and other deductions
At the time of sale, we also record estimates for certain sales deductions such as product returns and distributor discounts and incentives. We offer certain customers a limited right of return or replacement of product that is damaged in certain instances. When we cannot reasonably estimate the amount of future product returns and/or other sales deductions, we do not recognize revenue until the risk of product return and additional sales deductions have been substantially eliminated.
Milestone payments
In February 2015, under our exclusive license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, or the Servier Agreement, we received a €1.5 million milestone payment (or $1.7 million upon conversion from euros as of the date we received the funds) relating to the attainment of reimbursement approval for PIXUVRI in Spain. We allocated the milestone payment based on the relative-selling-price percentages originally used to allocate the arrangement consideration under the Servier Agreement. This revenue was accounted for under the milestone method of accounting since this milestone was determined to be substantive at the inception of the arrangement.
Cost of Product Sold
Cost of product sold includes third-party manufacturing costs, shipping costs, contractual royalties and other costs of PIXUVRI product sold. Cost of product sold also includes any necessary allowances for excess inventory that may expire and become unsalable.
Foreign Currency Translation and Transaction Gains and Losses
We record foreign currency translation adjustments and transaction gains and losses in accordance with ASC 830, Foreign Currency Matters. For our operations that have a functional currency other than the U.S. dollar, gains and losses resulting from the translation of the functional currency into U.S. dollars for financial statement presentation are not included in determining net loss, but are accumulated in the cumulative foreign currency translation adjustment account as a separate component of shareholders’ equity (deficit), except for intercompany transactions that are of a short-term nature with entities that are consolidated, combined or accounted for by the equity method in our consolidated financial statements. We and our subsidiaries also have transactions in foreign currencies other than the functional currency. We record transaction gains and losses in our consolidated statements of operations related to the recurring measurement and settlement of such transactions.
9
During the three months ended March 31, 2015, we have determined that the intercompany balance due from CTILS may no longer be considered of a short-term nature. Due to this change in accounting estimate, favourable unrealized foreign exchange gain of $0.9 million and unfavourable unrealized foreign exchange loss of $1.9 million was recorded in cumulative foreign currency translation adjustment account for the three and six months ended June 30, 2015, respectively. As of June 30, 2015, the intercompany balance due from CTILS was €22.7 million (or $25.3 million upon conversion from euros as of June 30, 2015).
Net Income (Loss) Per Share
Basic net income (loss) per share is calculated based on the net income (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net income (loss) per common share assumes the conversion of all dilutive convertible securities, such as convertible debt and convertible preferred stock using the if-converted method, and assumes the exercise or vesting of other dilutive securities, such as options, warrants and restricted stock using the treasury stock method.
Equity awards, warrants, and unvested share rights aggregating 14.7 million and 15.4 million shares for the three months ended June 30, 2015 and 2014, respectively, and 14.6 million and 15.4 million shares for the six months ended June 30, 2015 and 2014, respectively, prior to the application of the treasury stock method, were excluded from the calculation of diluted EPS because they are anti-dilutive.
Fair Value Measurement
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:
Level 1 - Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2 - Observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities, or other inputs that are observable directly or indirectly.
Level 3 - Unobservable inputs that are supported by little or no market activity, requiring an entity to develop its own assumptions.
If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
Recently Issued Accounting Standards
In May 2014, the Financial Accounting Standards Board, or the FASB, issued a new financial accounting standard which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2017. Early adoption is permitted as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. We are currently evaluating the impact of this accounting standard on our consolidated financial statements.
In August 2014, the FASB issued a new accounting standard which requires management to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern for each annual and interim reporting period and to provide related footnote disclosures in certain circumstances. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016. Early adoption is permitted. We are currently evaluating the impact of this accounting standard on our consolidated financial statements.
In April 2015, the FASB issued a new accounting standard which changes the presentation of debt issuance costs in financial statements. Under the new standard, an entity presents such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs is reported as interest expense. The accounting standard is effective for annual reporting periods beginning after December 15, 2015 and interim periods beginning after December 15, 2016. Early adoption is allowed for all entities for financial statements that have not been previously issued. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.
10
In July 2015, FASB issued a new accounting guidance on simplifying the measurement of inventory which requires that inventory within the scope of the guidance be measured at the lower of cost and net realizable value. Prior to the issuance of the standard, inventory was measured at the lower of cost or market (where market was defined as replacement cost, with a ceiling of net realizable value and floor of net realizable value less a normal profit margin). The accounting guidance is effective for annual reporting periods (including interim periods within those periods) beginning after December 15, 2016. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.
Reclassifications
Certain prior year items have been reclassified to conform to current year presentation.
2. |
Inventory |
The components of PIXUVRI inventory consisted of the following as of June 30, 2015 and December 31, 2014 (in thousands):
|
June 30, |
|
|
December 31, |
|
||
|
2015 |
|
|
2014 |
|
||
Finished goods |
$ |
1,011 |
|
|
$ |
850 |
|
Work-in-process |
|
2,596 |
|
|
|
3,332 |
|
Total inventories |
$ |
3,607 |
|
|
$ |
4,182 |
|
3. |
Long-term Debt |
Baxalta
In June 2015, we entered into the First Amendment, or the Baxalta Amendment, to the Development, Commercialization and License Agreement, or the License Agreement, dated as of November 14, 2013, with Baxter International Inc., or Baxter. Baxalta Incorporated and its affiliates, or Baxalta, have been assigned Baxter’s rights and obligations under the License Agreement. Pursuant to the Baxalta Amendment, two potential milestone payments in the aggregate amount of $32 million from Baxalta to us were accelerated from the schedule contemplated by the License Agreement relating to the following: the $12.0 million development milestone payment payable in connection with the regulatory submission to the EMA with respect to pacritinib, or the EMA Milestone, and the $20.0 million development milestone payment payable in connection with the first treatment dosing of the last patient enrolled in PERSIST-2, or the PERSIST-2 Milestone. Under the Baxalta Amendment, each of the two milestone advances bears interest at an annual rate of 9% percent until the earlier of the date of the first occurrence of the respective milestone or the date that the respective advance plus accrued interest is repaid in full.
In the event that pacritinib development is terminated due to certain specified reasons or the milestones are not achieved by respective deadlines (December 31, 2016 for the PERSIST-2 Milestone and March 31, 2017 for the EMA Milestone), we would be required to repay the respective advance to Baxalta in eight quarterly installments of $1.5 million relating to the EMA Milestone and $2.5 million relating to the PERSIST-2 Milestone, in each case beginning 30 days after the end of the calendar quarter of the first occurrence of such event, and a final payment equal to the remainder of the unpaid balance. Repayment of the advances will be accelerated in the event of the commencement of insolvency proceedings and certain other events of default. If a milestone is achieved, however, then we would remain entitled to the respective milestone payments. Additionally, in the event that we do not spend a specified amount on the development of pacritinib from the date of the amendment through February 29, 2016, payments to Baxalta in an amount equal to such deficiency may be required or credited against amounts owed to us under certain circumstances. In connection with this advance, we recorded debt issuance costs of $0.1 million. As of June 30, 2015, the outstanding balance of such advance was $32.0 million, and the unamortized issuance costs were $0.1 million.
11
Hercules
In June 2015, we entered into the Third Amendment, or the Third Amendment, to the Loan and Security Agreement, or the Loan Agreement, with Hercules Technology Growth Capital, Inc. and certain affiliates, or collectively, Hercules. Under the Third Amendment, Hercules agreed to provide term loans in an aggregate principal amount of up to $25.0 million, inclusive of the principal balance outstanding immediately prior to closing of the Third Amendment of $13.8 million, or collectively, the Term Loan Borrowings. We drew $6.2 million upon closing of the Third Amendment, resulting in a then-outstanding principal balance of $20.0 million under the Term Loan Borrowings. The remaining $5.0 million is available for borrowing at our option through June 30, 2016, subject to certain conditions. In connection with the Third Amendment, we paid a commitment fee of $15,000 and a facility charge of $0.3 million. The provision under the original Loan Agreement requiring us to pay a fee to Hercules of $1.3 million on the date of repayment of the borrowings thereunder was amended pursuant to the Third Amendment, such that the fee will now be payable on the earliest to occur of (1) October 1, 2016, (2) the date on which the Term Loan Borrowings are prepaid in full or (3) the date on which the Term Loan Borrowings become due and payable in full.
The interest rate on the Term Loan Borrowings floats at a rate per annum equal to 10.95% plus the amount by which the prime rate exceeds 3.25%. We are initially required to make interest payments only on a monthly basis, followed by the 36 equal monthly installments of principal and interest (mortgage style) commencing on January 1, 2016. The interest-only period may be extended by up to six months at our option if we achieve certain milestones by certain specified deadlines. We may elect to prepay some or all of the Term Loan Borrowings at any time subject to a prepayment fee, if any, pursuant to the terms of the Third Amendment. Under certain circumstances, we may be required to prepay the Term Loan Borrowings with proceeds of asset dispositions. The Term Loan Borrowings are secured by a first priority security interest on substantially all of our personal property except our intellectual property and subject to certain other exceptions.
In connection with the Third Amendment, we issued a warrant to Hercules to purchase shares of common stock. The warrant is exercisable for five years from the date of issuance for 0.3 million shares of common stock at an initial exercise price is $1.71 per share. The exercise price is subject to adjustment if, within six months after closing of the Third Amendment, we issue shares of common stock or securities that are exercisable or convertible into shares of common stock in transactions not registered under the Securities Act of 1933, as amended, under certain circumstances at an effective price per share of common stock that is less than the then-effective exercise price of the warrant. In such case, the exercise price shall automatically be reduced to equal the price per share of common stock in such transaction. The exercise price under the warrant and the number of shares for which the warrant is exercisable are each subject to certain customary adjustments as set forth in the agreement representing the warrant. Since the warrant does not meet the considerations necessary for equity classification under the applicable authoritative guidance, we determined the warrant is a liability instrument that is marked to fair value with changes in fair value recognized through earnings at each reporting period. The warrant is categorized as Level 2 in the fair value hierarchy as the significant inputs used in determining fair value are considered observable market data. As of the issuance date and June 30, 2015, we estimate the fair value of the warrant to be $0.4 million and $0.4 million, respectively.
The modified terms under the Third Amendment are considered substantially different as compared to the terms of the Loan Agreement immediately prior to the Third Amendment, pursuant to ASC 470-50, Modification and Extinguishment. As such, the Third Amendment was accounted for as a debt extinguishment, resulting in a loss on debt extinguishment of $1.2 million which is included in other non-operating expense.
As of June 30, 2015 and December 31, 2014, the outstanding principal balance under our Loan Agreement, as amended by the Third Amendment, was $20.0 million and $18.5 million, unamortized debt discount was $0.4 million and $1.1 million, and unamortized issuance costs were $0.1 million and $0.2 million, respectively.
4. |
Legal Proceedings |
As previously disclosed, on December 10, 2009, the Commissione Nazionale per le Società e la Borsa (which is the public authority responsible for regulating the Italian securities markets), or CONSOB, sent us a notice claiming, among other things, violation of the provisions of Section 114, paragraph 1 of the Italian Legislative Decree no. 58/98 due to the asserted late disclosure of the contents of the opinion expressed by Stonefield Josephson, Inc., an independent registered public accounting firm, with respect to our 2008 financial statements. However, we understand that, according to applicable Italian law provisions as interpreted by applicable case law, CONSOB’s right to pursue a pecuniary administrative sanction is considered barred due to the passage of time.
12
The Italian Tax Authority, or the ITA, issued notices of assessment to CTI (Europe) based on the ITA’s audit of CTI (Europe)’s VAT returns for the years 2003, 2005, 2006 and 2007, or, collectively, the VAT Assessments. The ITA audits concluded that CTI (Europe) did not collect and remit VAT on certain invoices issued to non-Italian clients for services performed by CTI (Europe). We believe that the services invoiced were non-VAT taxable consultancy services and that the VAT returns are correct as originally filed. We are defending ourselves against the assessments both on procedural grounds and on the merits of the case, although we can make no assurances regarding the ultimate outcomes of these cases. As of December 31, 2012, we reversed the entire reserve we had previously recorded relating to the VAT Assessments after having received favorable court rulings. In January 2013, our then remaining deposit for the VAT Assessments was refunded to us. The current status of the legal proceedings surrounding each respective VAT year return at issue is as follows:
2003. In June 2013, the Regional Tax Court issued decision no. 119/50/13 in regards to the 2003 VAT assessment, which accepted the appeal of the ITA and reversed the previous decision of the Provincial Tax Court. In January 2014, we were notified that the ITA requested partial payment of the 2003 VAT assessment in the amount of €0.4 million (or $0.6 million upon conversion from euros at the time of payment in March 2014). We believe that the decision of the Regional Tax Court did not carefully take into account our arguments and the documentation we filed, and in January 2014, we appealed such decision to the Italian Supreme Court both on procedural grounds and on the merits of the case.
2005, 2006 and 2007. The ITA has appealed to the Italian Supreme Court the decisions of the respective appellate court with respect to each of the 2005, 2006 and 2007 VAT returns.
If the final decisions of the Italian Supreme Court for the VAT Assessments are unfavorable to us, we may incur up to $10.5 million in losses for the VAT amount assessed including penalties, interest and fees upon conversion from euros as of June 30, 2015.
On May 13, 2015, the Company (as nominal defendant) and our directors (as individual defendants) entered into a memorandum of understanding to settle the pending lawsuit in King County Superior Court in the State of Washington docketed as Lopez & Gilbert v. Nudelman, et al ., Case No. 14-2-18941-9 SEA, or the Derivative Lawsuit, the Settlement. The Settlement must still be memorialized in a stipulation of settlement to be filed with the court, followed by both preliminary and final approval by the court. The provisions of the Settlement include the following terms subject to court approval:
· |
We will cancel and the non-employee directors will agree to the rescission of all currently outstanding equity awards that we previously granted to non-employee directors that included performance-based vesting metrics and as to which the performance goals remained unsatisfied as of May 13, 2015; |
· |
Our current non-employee directors will agree to hold (not transfer or sell or encumber in any way) until September 14, 2015 shares of our stock that they currently own and that we awarded to them during 2011, or at any time after 2011 to the present, and that, at the time of the award by us, was fully-vested and unrestricted; |
· |
We will cap the total annual compensation provided by it to its non-employee directors for each of 2015 and 2016. Such annual compensation cap for each non-employee director for each of 2015 and 2016 will be the greater of (i) $375,000, plus, as to our Board Chairman, an additional $100,000, or (ii) the 75th percentile of compensation paid by a group of peer companies to their non-employee directors (and, in the case of our Chairman, the 75th percentile of compensation paid by such peers who have a non-employee director chair of their respective board of directors to such non-employee director chairs). The peer group for these purposes will be selected based on advice from the outside compensation consultant. For purposes of the compensation cap and the peer group comparison, compensation will be determined and measured consistent with the rules under Item 402 of Regulation S-K under the Securities Exchange Act of 1934, as amended, and based on publicly-available information at the applicable time; and |
· |
We will implement, if not already implemented, within 90 days following final approval of the Settlement by the court, and maintain until at least the end of calendar year 2017 the following: an annual board discussion of non-employee director compensation philosophy; the use of a compensation consultant to advise the Compensation Committee on material decisions concerning non-employee director compensation issues and compare our non-employee director compensation program to a group of our peers; the use of plain language in our compensation-related public filings; and obtain confirmation from our legal department and outside legal counsel advising on executive compensation matters that any contemplated non-employee director awards do not materially violate the applicable plan or materially fail to comply with applicable law. |
We currently anticipate that we will be obligated to pay an amount for plaintiffs’ legal fees and expenses, which will ultimately be subject to court approval. However, in light of our existing insurance coverage, we do not anticipate that the payment of the ultimate fee award will have a material effect on our financial position or results of operations. The amount of our reasonable estimate of liability as of June 30, 2015, though immaterial, was accrued for in our financial statements as of June 30, 2015.
13
5. |
Share-based Compensation Expense |
The following table summarizes share-based compensation expense for the three and six months ended June 30, 2015 and 2014, which was allocated as follows (in thousands):
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
2015 |
|
|
2014 |
|
|
2015 |
|
|
2014 |
|
||||
Research and development |
$ |
762 |
|
|
$ |
1,034 |
|
|
$ |
1,752 |
|
|
$ |
1,816 |
|
Selling, general and administrative |
|
2,011 |
|
|
|
4,322 |
|
|
|
5,357 |
|
|
|
11,369 |
|
Total share-based compensation expense |
$ |
2,773 |
|
|
$ |
5,356 |
|
|
$ |
7,109 |
|
|
$ |
13,185 |
|
For the three and six months ended June 30, 2015 and 2014, we incurred share-based compensation expense due to the following types of awards (in thousands):
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
2015 |
|
|
2014 |
|
|
2015 |
|
|
2014 |
|
||||
Performance rights |
$ |
423 |
|
|
$ |
191 |
|
|
$ |
841 |
|
|
$ |
694 |
|
Restricted stock |
|
1,586 |
|
|
|
3,679 |
|
|
|
4,958 |
|
|
|
9,648 |
|
Options |
|
764 |
|
|
|
1,486 |
|
|
|
1,310 |
|
|
|
2,843 |
|
Total share-based compensation expense |
$ |
2,773 |
|
|
$ |
5,356 |
|
|
$ |
7,109 |
|
|
$ |
13,185 |
|
6. |
Other Comprehensive Income (Loss) |
Total accumulated other comprehensive income (loss) consisted of the following (in thousands):
|
Net Unrealized Loss on Securities Available-For- Sale |
|
|
Foreign Currency Translation Adjustments |
|
|
Unrealized foreign exchange loss on intercompany balance |
|
|
Accumulated Other Comprehensive Loss |
|
||||
December 31, 2014 |
$ |
(490 |
) |
|
$ |
(6,009 |
) |
|
$ |
— |
|
|
$ |
(6,499 |
) |
Current period other comprehensive income (loss) |
|
(8 |
) |
|
|
1,495 |
|
|
|
(1,874 |
) |
|
|
(387 |
) |
June 30, 2015 |
$ |
(498 |
) |
|
$ |
(4,514 |
) |
|
$ |
(1,874 |
) |
|
$ |
(6,886 |
) |
7. |
Leases |
Our deferred rent balance was $4.2 million as of June 30, 2015, of which $0.4 million was included in other current liabilities and $3.8 million was included in other liabilities. As of December 31, 2014, our deferred rent balance was $4.4 million, of which $0.4 million was included in other current liabilities and $4.0 million was included in other liabilities.
14
This Quarterly Report on Form 10-Q may contain, in addition to historical information, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and should be read in conjunction with the Condensed Consolidated Financial Statements and the related Notes included in Part I, Item 1 of this Quarterly Report on Form 10-Q. When used in this Quarterly Report on Form 10-Q, terms such as “anticipates,” “believes,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “should,” or “will” or the negative of those terms or other comparable terms are intended to identify such forward-looking statements. Such statements, which include statements concerning sufficiency of cash resources and other projections, product manufacturing and sales, research and development expenses, selling, general and administrative expenses, financings and additional losses, are subject to known and unknown risks and uncertainties, including, but not limited to, those discussed below and elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the fiscal year ending December 31, 2014, or the 2014 Form 10-K, particularly in “Factors Affecting Our Business, Financial Condition, Operating Results and Prospects,” that could cause actual results, levels of activity, performance or achievements to differ significantly from those projected. Although we believe that expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We will not update any of the forward-looking statements after the date of this Quarterly Report on Form 10-Q to conform these statements to actual results or changes in our expectations. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this Quarterly Report on Form 10-Q.
OVERVIEW
We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and health care providers. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners. We are currently concentrating our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are primarily focused on commercializing PIXUVRI® (pixantrone), or PIXUVRI, in the European Union, or the E.U., for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, or NHL, and conducting a Phase 3 clinical trial program evaluating pacritinib for the treatment of adult patients with myelofibrosis to support regulatory submission for approval in the United States, or the U.S., and Europe. We are also evaluating pacritinib in early phase clinical trials as treatment for other blood-related cancers.
PIXUVRI
PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties. In May 2012, the European Commission granted conditional marketing authorization in the E.U. for PIXUVRI as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell NHL. PIXUVRI is the first approved treatment in the E.U. for patients with multiply relapsed or refractory aggressive B-cell NHL who have failed two or three prior lines of therapy. As part of the conditional marketing authorization, we are required to conduct a post-authorization trial, or PIX306, which compares PIXUVRI and rituximab with gemcitabine and rituximab in the setting of aggressive B-cell NHL.
PIXUVRI is currently available in Austria, Denmark, Finland, France, Germany, Israel, Italy, Netherlands, Norway, Sweden and the United Kingdom, or the U.K., and has achieved reimbursement decisions under varying conditions in England/Wales, Italy, France, Germany, Netherlands and Spain. In almost all European markets, pricing and availability of prescription pharmaceuticals are subject to governmental control. Accordingly, any future revenues are dependent on market acceptance of PIXUVRI, the reimbursement decisions made by the governmental authorities in each country where PIXUVRI is available for sale and other factors. Although we do not have and are not currently pursuing regulatory approval of PIXUVRI in the U.S., we may reevaluate a possible submission strategy in the U.S. based on the data generated from PIX306.
We have established a commercial organization, including sales, marketing, supply chain management and reimbursement capabilities, to commercialize PIXUVRI in certain countries in the E.U. In September 2014, we entered into an exclusive license and collaboration agreement, or the Servier Agreement, with Les Laboratoires Servier and Institut de Recherches Internationales Servier, or collectively, Servier, with respect to the development and commercialization of PIXUVRI. Under the Servier Agreement, we retain full commercialization rights to PIXUVRI in Austria, Denmark, Finland, Germany, Israel, Norway, Sweden, Turkey, the U.K. and the U.S., while Servier has exclusive rights to commercialize PIXUVRI in all other countries. For additional information on our collaboration with Servier, see Part I, Item 2, “License Agreements and Milestone Activities – Servier.”
15
Pacritinib
Our lead development candidate, pacritinib, is an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R. Pacritinib is currently being evaluated in two Phase 3 clinical trials, known as the PERSIST program, for adult patients with myelofibrosis. Myelofibrosis is a rare blood cancer associated with significantly reduced quality of life and shortened survival. As the disease progresses, the body slows production of important blood cells and within one year of diagnosis, the incidence of disease-related thrombocytopenia (very low blood platelet counts), severe anemia and red blood cell transfusion requirements increase significantly. Among other complications, most patients with myelofibrosis present with enlarged spleens (splenomegaly), as well as many other potentially devastating physical symptoms such as abdominal discomfort, bone pain, feeling full after eating little, severe itching, night sweats and extreme fatigue. We believe pacritinib may offer an advantage over other JAK inhibitors through effective treatment of symptoms while having less treatment-emergent thrombocytopenia and anemia than has been seen in the currently approved JAK inhibitor.
We are pursuing a broad approach to advancing pacritinib for adult patients with myelofibrosis by conducting two Phase 3 clinical trials: one in a broad set of patients without limitations on blood platelet counts, the PERSIST-1 trial; and the other in patients with low platelet counts, the PERSIST-2 trial.
In October 2013, we reached an agreement with the Food and Drug Administration, or the FDA, on a Special Protocol Assessment for PERSIST-2. In August 2014, pacritinib was granted Fast Track designation by the FDA for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease-related thrombocytopenia, patients experiencing treatment-emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant of, or whose symptoms are sub-optimally managed on, other JAK2 therapy. The FDA’s Fast Track process is designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The PERSIST-1 and PERSIST-2 clinical trials are intended to support a potential regulatory submission to the FDA or the European Medicines Agency, or the EMA.
In March 2015, we reported top-line results for the primary endpoint from PERSIST-1, which is a randomized Phase 3 registration-directed trial examining pacritinib for the treatment of patients with myelofibrosis. PERSIST-1 met its primary endpoint of spleen volume reduction (35 percent or greater from baseline to Week 24 by magnetic resonance imaging or computerized tomography scan) when compared with physician-specified best available therapy, excluding treatment with JAK2 inhibitors, in the intent-to-treat population, with statistically significant activity observed in patients irrespective of their initial platelet count, including patients with very low platelet counts at study entry.
In May 2015, data from PERSIST-1 showed that compared to best available therapy (exclusive of a JAK inhibitor), pacritinib therapy resulted in a significantly higher proportion of patients with spleen volume reduction and control of disease-related symptoms. Treatment with pacritinib resulted in improvements in severe thrombocytopenia and severe anemia, eliminating the need for blood transfusions in a quarter of patients who were transfusion dependent at the time of enrollment. Gastrointestinal symptoms were the most common adverse events and typically lasted for approximately one week. A limited number of patients discontinued treatment due to side effects. There were no Grade 4 gastrointestinal events reported. These results were presented at a late-breaking oral session at the 51st Annual Meeting of the American Society of Clinical Oncology Annual Meeting.
In June 2015, results from PERSIST-1 patient-reported outcome (PRO) and other quality of life measures presented at a late-breaking oral session at the 20th Congress of the European Hematology Association showed significant improvements in symptom score with pacritinib therapy compared to best available therapy (exclusive of a JAK inhibitor) across the symptoms reported in the presentation.
Under the Baxalta Agreement (defined below), we share joint commercialization rights to pacritinib with Baxalta Incorporated and its affiliates, or Baxalta, in the U.S., while Baxalta has exclusive commercialization rights for all indications outside the U.S. For additional information relating to the Baxalta Agreement, see Part I, Item 2, “License Agreements and Milestone Activities—Baxalta”.
Tosedostat
Our earlier stage product candidate, tosedostat, is a novel oral, once-daily aminopeptidase inhibitor that has demonstrated significant responses in patients with acute myeloid leukemia, or AML. It is currently being evaluated in several Phase 2 cooperative group-sponsored trials and investigator-sponsored trials. These trials are evaluating tosedostat in combination with hypomethylating agents in AML and myelodysplastic syndrome, which are cancers of the blood and bone marrow. We anticipate data from these signal-finding trials may be used to determine an appropriate design for a potential Phase 3 trial.
16
In June 2015, data from an investigator-sponsored Phase 2 trial of tosedostat in elderly patients with either primary AML or AML that has evolved from myelodysplastic syndrome showed the combination of tosedostat with low-dose cytarabine/Ara-C resulted in an overall response rate of 54 percent, with 45 percent of patients achieving durable complete responses. These findings were also presented at the European Hematology Association.
Financial summary
Our revenues are generated from a combination of PIXUVRI sales and collaboration and license agreements. Collaboration revenues reflect the earned amount of upfront payments and milestone payments under our product collaborations. Total revenues were $1.1 million for the three months ended June 30, 2015, compared to $1.3 million for the same period in 2014. Total revenues increased to $3.8 million for the six months ended June 30, 2015, compared to $2.8 million for the same period in 2014. Our loss from operations for the three and six months ended June 30, 2015 was $31.0 million and $58.5 million, respectively, compared to a loss of $26.7 million and $54.3 million during the same periods in 2014. Our results of operations may vary substantially from year to year and from quarter to quarter and, as a result, you should not rely on them as being indicative of our future performance.
As of June 30, 2015, we had cash and cash equivalents of $54.9 million.
RESULTS OF OPERATIONS
Three and six months ended June 30, 2015 and 2014
Product sales, net. Net product sales from PIXUVRI were $0.8 million and $1.1 million for the three months ended June 30, 2015 and 2014, and $1.7 million and $2.4 million for the six months ended June 30, 2015 and 2014, respectively. We sell PIXUVRI through a limited number of wholesale distributors and directly to health care providers in Austria, Denmark, Finland, Germany, Norway, Sweden and England. Servier is responsible for distribution of PIXUVRI in the respective countries in its territory. We generally record product sales upon receipt of the product by the health care provider or distributor at which time title and risk of loss pass.
Product sales are recorded net of distributor discounts, estimated government-mandated discounts and rebates, trade discounts and estimated product returns. The decrease in net product sales of $0.3 million for the three months ended June 30, 2015 and $0.8 million for the six months ended June 30, 2015 compared to the same periods in 2014 was primarily related to the decline in average exchange rate of the euro for our euro-denominated sales as well as pricing and volume variances between the periods presented. Any expansion of our commercial operations in E.U. (including with regard to sales of PIXUVRI) may increase our exposure to fluctuations in foreign currency exchange rates. Any future revenues are dependent on market acceptance of PIXUVRI, the reimbursement decisions made by governmental authorities in each country where PIXUVRI is available for sale and other factors.
Gross sales is defined as our contracted reimbursement price in each country. Gross sales from PIXUVRI were $0.9 million and $1.2 million for the three months ended June 30, 2015 and 2014, and $1.7 million and $2.5 million for the six months ended June 30, 2015 and 2014, respectively.
Product sales, net for the three months ended June 30, 2015 and 2014 includes a provision for discounts, rebates and other of $10,000 and $15,000 for current period sales, respectively. Product sales, net for the six months ended June 30, 2015 and 2014 includes a provision for discounts, rebates and other of $18,000 and $30,000 for current period sales, respectively. The provision for discounts, rebates and other during the periods presented primarily relates to distributor discounts on PIXUVRI product sold.
The provision for product returns relates to a limited right of return or replacement that we offer to certain customers. During the three and six months ended June 30, 2015, the provision of $1,000 and $2,000 was recorded for current period sales, respectively. The reversal adjustment for $1,000 was recorded during the six months ended June 30, 2015 for prior period sales. During the three months and six months ended June 30, 2014, the provision of $35,000 and $38,000 was recorded for current period sales, respectively.
During the three months ended June 30, 2015 and 2014, payments and credits of $10,000 and $15,000 were applied towards provision for discounts, rebates and other for current period sales, respectively. During the three months ended June 30, 2014, payments and credits of $7,000 were applied towards such provision for prior period sales. During the six months ended June 30, 2015 and 2014, payments and credits of $18,000 and $30,000 were applied towards such provision for current period sales and $6,000 and $76,000 for prior period sales, respectively. All rebate payments made during the periods presented relate to 2013 sales activity.
As of June 30, 2015, the balances of reserve for product returns of $11,000, and reserve for discounts, rebates and other of $30,000, are reflected in accounts receivable and accrued expenses, respectively. As of June 30, 2014, the balances were $77,000 and $0.1 million for product returns reserve and reserve for discounts, rebates and other, respectively.
17
License and Contract Revenues
License and contract revenues are summarized as follows (in thousands):
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||
|
|
2015 |
|
2014 |
|
|
2015 |
|
2014 |
|
||||
Baxalta |
Development services revenue |
$ |
223 |
|
$ |
195 |
|
|
$ |
411 |
|
$ |
338 |
|
|
Total Baxalta |
|
223 |
|
|
195 |
|
|
|
411 |
|
|
338 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Servier |
License revenue |
|
- |
|
|
- |
|
|
|
1,622 |
|
|
- |
|
|
Development services revenue |
|
25 |
|
|
- |
|
|
|
131 |
|
|
- |
|
|
Royalty revenue |
|
3 |
|
|
- |
|
|
|
10 |
|
|
- |
|
|
Total Servier |
|
28 |
|
|
- |
|
|
|
1,763 |
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total license and contract revenue |
$ |
251 |
|
$ |
195 |
|
|
$ |
2,174 |
|
$ |
338 |
|
Baxalta
The license and contract revenue under the Baxalta Agreement for each of the three months ended June 30, 2015 and 2014 includes $0.2 million of development services revenue recognized from the upfront payment we received in connection with the Baxalta Agreement in 2013. $0.4 million and $0.3 million of such revenue was recognized for the six months ended June 30, 2015 and 2014, respectively. For additional information relating to the Baxalta Agreement, see Part I, Item 2, “License Agreements and Milestone Activities—Baxalta”.
Servier
The license and contract revenue under the Servier Agreement for the six months ended June 30, 2015 includes $1.6 million of license revenue and $0.1 million of development services revenue. In February 2015, we received a €1.5 million milestone payment (or $1.7 million using the currency exchange rate as of the date we received the funds) relating to the attainment of reimbursement approval for PIXUVRI in Spain. We allocated the milestone payment in the table above based on the relative-selling-price percentages originally used to allocate the arrangement consideration under the Servier Agreement. There were no such milestone payments received in other periods presented. For additional information on our collaboration with Servier, see Part I, Item 2, “License Agreements and Milestone Activities – Servier.”
The following table illustrates such balances of deferred revenue under each of the Baxalta Agreement and the Servier Agreement as of June 30, 2015 and December 31, 2014 (in thousands):
|
|
June 30, 2015 |
|
|
December 31, 2014 |
|
||
Current portion of deferred revenue |
|
|
|
|
|
|
|
|
|
Baxalta |
$ |
611 |
|
|
$ |
724 |
|
|
Servier |
|
102 |
|
|
|
102 |
|
|
Other |
|
134 |
|
|
|
- |
|
Total current portion of deferred revenue |
|
847 |
|
|
|
826 |
|
|
|
|
|
|
|
|
|
|
|
Deferred revenue, less current portion |
|
|
|
|
|
|
|
|
|
Baxalta |
|
762 |
|
|
|
1,059 |
|
|
Servier |
|
668 |
|
|
|
720 |
|
Total deferred revenue, less current portion |
|
1,430 |
|
|
|
1,779 |
|
|
|
|
|
|
|
|
|
|
|
Total deferred revenue |
$ |
2,277 |
|
|
$ |
2,605 |
|
18
Operating costs and expenses
Cost of product sold. Cost of product sold is related to sales of PIXUVRI. Cost of product sold for each of the three months ended June 30, 2015 and 2014 was $0.2 million. While the cost of product sold expense remained unchanged between periods, the number of units sold declined in the three months ended June 30, 2015. In addition, the euro experienced a decline between comparable periods. These changes were partially offset by the sale of higher cost inventory during the three months ended June 30, 2015. Cost of product sold for the six months ended June 30, 2015 and 2014 was $0.4 million and $0.3 million, respectively. This increase was primarily due to the sale of higher cost inventory, despite the sale of fewer units during the six months ended June 30, 2015. Additionally, we recorded a write-off of $37,000 for expired inventory during the current period while there was no such write-off recorded in the comparable period. The decline in the euro between comparable periods partially offset the increase in cost of product sold. We began capitalizing costs related to the production of PIXUVRI in February 2012 upon receiving a positive opinion for conditional marketing authorization by the Committee for Medicinal Products for Human Use, or the CHMP, which is a committee of the EMA. While we tracked the quantities of individual PIXUVRI product lots, we did not track manufacturing costs prior to capitalization, and therefore, the manufacturing cost of PIXUVRI produced prior to capitalization is not reasonably determinable. Most of this reduced-cost inventory is expected to be available for us to use commercially. The timing of the sales of such reduced-cost inventory and its impact on gross margin is dependent on the level of PIXUVRI sales as well as our ability to utilize this inventory prior to its expiration date. We expect that our cost of product sold as a percentage of product sales will increase in future periods as PIXUVRI product manufactured and expensed prior to capitalization is sold. At this time, we cannot reasonably estimate the timing or rate of consumption of reduced-cost PIXUVRI product manufactured and expensed prior to capitalization, and we are unable to provide our estimate of cost of goods sold as a percentage of product revenue once such inventory is exhausted.
Research and development expenses. Our research and development expenses for compounds under development and preclinical development were as follows (in thousands):
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
2015 |
|
|
2014 |
|
|
2015 |
|
|
2014 |
|
||||
Compounds: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PIXUVRI |
$ |
4,147 |
|
|
$ |
1,379 |
|
|
$ |
8,323 |
|
|
$ |
2,580 |
|
Pacritinib |
|
9,181 |
|
|
|
7,172 |
|
|
|
17,062 |
|
|
|
13,136 |
|
Opaxio |
|
(10 |
) |
|
|
133 |
|
|
|
12 |
|
|
|
241 |
|
Tosedostat |
|
226 |
|
|
|
124 |
|
|
|
259 |
|
|
|
284 |
|
Operating expenses |
|
5,559 |
|
|
|
4,896 |
|
|
|
10,585 |
|
|
|
9,542 |
|
Research and preclinical development |
|
217 |
|
|
|
313 |
|
|
|
550 |
|
|
|
413 |
|
Total research and development expenses |
$ |
19,320 |
|
|
$ |
14,017 |
|
|
$ |
36,791 |
|
|
$ |
26,196 |
|
19
Costs for our compounds include external direct expenses such as principal investigator fees, charges from clinical research organizations, or CROs, and contract manufacturing fees incurred for preclinical, clinical, manufacturing and regulatory activities associated with preparing the compounds for submissions of New Drug Applications, or NDAs, or similar regulatory filings to the FDA, the EMA or other regulatory agencies outside the U.S. and Europe, as well as upfront license fees for acquired technology. Subsequent to receiving a positive opinion for conditional approval of PIXUVRI in the E.U. from the EMA’s CHMP, costs associated with commercial batch production, quality control, stability testing, and certain other manufacturing costs of PIXUVRI were capitalized as inventory. Operating expenses include our personnel and an allocation of occupancy, depreciation and amortization expenses associated with developing these compounds. Research and preclinical development costs primarily include costs associated with external laboratory services associated with the compound licensed to and under development by Aequus Biopharma, Inc. We are not able to capture the total cost of each compound because we do not allocate operating expenses to all of our compounds. External direct costs incurred by us as of June 30, 2015 were $102.3 million for PIXUVRI (excluding costs prior to our 2004 merger with Novuspharma S.p.A, formerly a public pharmaceutical company located in Italy), $63.9 million for pacritinib (excluding costs for pacritinib prior to our acquisition of certain assets from S*BIO Pte Ltd, or S*BIO, in May 2012 and $29.1 million of in-process research and development expenses associated with the acquisition of certain assets from S*BIO), $227.3 million for Opaxio, $11.7 million for tosedostat (excluding costs for tosedostat prior to our co-development and license agreement with Chroma Therapeutics Limited, or Chroma, in 2011 and $21.9 million of in-process research and development expenses associated with the acquisition of certain assets from Chroma). External direct costs incurred by us as of June 30, 2015 were $9.6 million for brostallicin. We did not expend material resources on brostallicin during the periods presented. Research and development expenses increased to $19.3 million for the quarter ended June 30, 2015 compared to $14.0 million for the quarter ended June 30, 2014. Research and development expenses increased to $36.8 million for the six months ended June 30, 2015 compared to $26.2 million for the same period in 2014. These increases were primarily due to increased costs incurred with our PIX306 trial and our pacritinib development program. The increase in the pacritinib program is primarily due to clinical and non-clinical Phase 1 studies to support a potential NDA filing, in addition to the ramp-up of the PERSIST-2 trial. These increases were partially offset by decreases due to completion of enrollment in the PERSIST-1 trial. The increase in operating expenses is primarily attributed to personnel costs and other expenses in support of our development programs.
Regulatory agencies, including the FDA and EMA, regulate many aspects of a product candidate’s life cycle, including research and development and preclinical and clinical testing. We will need to commit significant time and resources to develop our current and any future product candidates. Our product candidates pacritinib, tosedostat and Opaxio are currently in clinical development, and our product PIXUVRI, which is currently being commercialized in parts of Europe, is undergoing a post-authorization trial. Many drugs in human clinical trials fail to demonstrate the desired safety and efficacy characteristics. We are unable to provide the nature, timing and estimated costs of the efforts necessary to complete the development of pacritinib, tosedostat and Opaxio, and to complete the post-authorization PIX306 trial of PIXUVRI, because, among other reasons, we cannot predict with any certainty the pace of patient enrollment of our clinical trials, which is a function of many factors, including the availability and proximity of patients with the relevant condition and the availability of the compounds for use in the applicable trials. We rely on third parties to conduct clinical trials, which may result in delays or failure to complete trials if the third parties fail to perform or meet applicable standards. Even after a clinical trial is enrolled, preclinical and clinical data can be interpreted in different ways, which could delay, limit or preclude regulatory approval and advancement of this compound through the development process. We or regulatory authorities may suspend clinical trials at any time on the basis that the participants are being exposed to unacceptable health risks. Even if our drugs progress successfully through initial human testing in clinical trials, they may fail in later stages of development. A number of companies in the pharmaceutical industry, including us, have suffered significant setbacks in advanced clinical trials, even after reporting promising results in earlier trials. For these reasons, among others, we cannot estimate the date on which clinical development of our product candidates will be completed, if ever, or when we will generate material net cash inflows from PIXUVRI or be able to begin commercializing pacritinib, tosedostat or Opaxio to generate material net cash inflows. In order to generate revenue from these compounds, our product candidates need to be developed to a stage that will enable us to commercialize, sell or license related marketing rights to third parties.
We also enter into collaboration agreements for the development and commercialization of our product candidates. We cannot control the amount and timing of resources our collaborators devote to product candidates, which may also result in delays in the development or marketing of products. Because of these risks and uncertainties, we cannot accurately predict when or whether we will successfully complete the development of our product candidates or the ultimate product development cost.
The risks and uncertainties associated with completing development on schedule and the consequences to operations, financial position and liquidity if the project is not timely completed are discussed in more detail in our risk factors, which can be found in Part II, Item 1A of this Quarterly Report on Form 10-Q.
20
Selling, general and administrative expenses. Selling, general and administrative expenses were $12.6 million for the three months ended June 30, 2015 as compared to $13.8 million for the same period in 2014. This decrease was primarily due to a $2.3 million decrease in non-cash share-based compensation, partially offset by increases in other expenses, including settlement expense, and also an increase in bad debt expense associated with PIXUVRI trade receivables. Selling, general and administrative expenses were $24.9 million for the six months ended June 30, 2015 as compared to $30.5 million for the same period in 2014. This decrease was primarily due to a $6.0 million decrease in non-cash share-based compensation and also a decrease in a provision for tax assessments, partially offset by increases in other expenses, including settlement expense.
Other operating expense. Other operating expense of $0.3 million for the six months ended June 30, 2015 relates to the payment made to Novartis International Pharmaceutical Ltd., or Novartis, as a result of the milestone payment we received under the Servier Agreement relating to the attainment of reimbursement approval for PIXUVRI in Spain.
Non-operating income and expenses
Interest expense. Interest expense for the three and six months ended June 30, 2015 and for the same periods in 2014 was primarily related to our senior secured term loan.
Amortization of debt discount and issuance costs. Amortization of debt discount and issuance costs for the three and six months ended June 30, 2015 and for the same periods in 2014 was primarily related to our senior secured term loan.
Foreign exchange gain (loss). The foreign exchange gain (loss) for the three and six months ended June 30, 2015 and for the same periods in 2014 is due to fluctuations in foreign currency exchange rates, primarily related to operations in our European branches and subsidiaries denominated in foreign currencies.
Other non-operating expense. Other non-operating expense for the three and six months ended June 30, 2015 was primarily related to a $1.2 million loss on debt extinguishment in connection with our entry into an amendment to our senior secured term loan agreement. Please see Part I, Item 1, Note 3, Long-Term Debt, in this Quarterly Report on Form 10-Q, which note is incorporated herein by reference, for further information. Other non-operating expense for the same periods in 2014 was primarily related to the change in fair value of the warrant issued pursuant to our senior secured term loan agreement.
LIQUIDITY AND CAPITAL RESOURCES
Overview
Cash and cash equivalents. As of June 30, 2015, we had $54.9 million in cash and cash equivalents.
Net cash used in operating activities. Net cash used in operating activities increased to $48.9 million during the six months ended June 30, 2015 as compared to $38.4 million for the same period in 2014. This increase was primarily due to research and development activities incurred in connection with our pacritinib development program and our PIX306 trial.
Net cash used in investing activities. Net cash used in investing activities decreased to $24,000 for the six months ended June 30, 2015 compared to $58,000 for the same period in 2014 due to a decrease in purchases of property and equipment.
Net cash provided by (used in) financing activities. Net cash provided by financing activities was $32.5 million for the six months ended June 30, 2015 compared to $0.1 million net cash used in financing activities for the same period in 2014. The increase in net cash provided was primarily due to the proceeds we received in June 2015 under our senior secured term loan agreement and as a result of the Baxalta milestone advance received, each as discussed below.
In June 2015, we amended our senior secured term loan agreement pursuant to which we received $6.2 million (less fees and expenses) in additional borrowed funds, thereby resulting in an outstanding principal balance thereunder of $20.0 million as of June 30, 2015. An additional $5.0 million is available for borrowing at our option through June 30, 2016, subject to the satisfaction of certain conditions. For a discussion of such loan agreement, please see Part I, Item 1, Note 3, Long-Term Debt, in this Quarterly Report on Form 10-Q.
In June 2015, we received an advance of potential milestone payments from Baxalta in the aggregate amount of $32 million relating to the development milestone payment payable to us in connection with the regulatory submission to the EMA with respect to pacritinib, or the EMA Milestone, and the development milestone payment payable to us for the first treatment dosing of the last patient enrolled in PERSIST-2, or the PERSIST-2 Enrollment Milestone. For a discussion of the terms of such advanced funds, including the applicable interest rate and events that may trigger repayment thereof, see Part I, Item 2, “License Agreements and Milestone Activities—Baxalta”.
21
Capital Resources
We have prepared our financial statements assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. However, we believe that our present financial resources, together with milestone payments projected to be received under certain of our contractual agreements, our ability to control costs and expected net sales of PIXUVRI, will only be sufficient to fund our operations through the fourth quarter of 2015. This raises substantial doubt about our ability to continue as a going concern. Further, we have incurred net losses since inception and expect to generate losses for the next few years primarily due to research and development costs for PIXUVRI, pacritinib, Opaxio and tosedostat. We have historically funded our operations through equity financings, borrowings and funds obtained under product collaborations, any or all of which may not be available to us in the future. As of June 30, 2015, our available cash and cash equivalents were $54.9 million. We had an outstanding principal balance under our senior secured term loan agreement of $20.0 million, and an additional $5.0 million is available for borrowing thereunder at our option through June 30, 2016, subject to the lender’s receipt of the following: (1) on or prior to December 31, 2015, satisfactory evidence of the achievement of full patient enrollment in PERSIST-2; and (2) on or prior to June 30, 2016, satisfactory evidence of the achievement of positive data in connection for PERSIST-2. We also had an outstanding balance of $32 million classified as debt as a result of the Baxalta milestone advance received in June 2015. Refer to the discussion above for further details regarding these borrowings.
Financial resource forecasts are subject to change as a result of a variety of risks and uncertainties. Changes in manufacturing, developments in and expenses associated with our clinical trials and the other factors identified under “Capital Requirements” below may consume capital resources earlier than planned. Additionally, we may not receive the anticipated milestone payments or achieve projected net sales from PIXUVRI. Due to these and other factors, the foregoing forecast for the period for which we will have sufficient resources to fund our operations may fail.
Capital Requirements
We will need to raise additional funds to operate our business. We may seek to raise such capital through public or private equity financings, partnerships, collaborations, joint ventures, disposition of assets, debt financings or restructurings, bank borrowings or other sources of financing. However, we have a limited number of authorized shares of common stock available for issuance and additional funding may not be available on favorable terms or at all. If additional funds are raised by issuing equity securities, substantial dilution to existing shareholders may result. If we fail to obtain additional capital when needed, our ability to operate as a going concern will be harmed, and we may be required to delay, scale back or eliminate some or all of our research and development programs, reduce our selling, general and administrative expenses, be unable to attract and retain highly qualified personnel, refrain from making our contractually required payments when due (including debt payments) and/or may be forced to cease operations, liquidate our assets and possibly seek bankruptcy protection.
Our future capital requirements will depend on many factors, including:
· |
changes in manufacturing; |
· |
developments in and expenses associated with our clinical trials and other research and development activities; |
· |
acquisitions of compounds or other assets; |
· |
ability to generate sales of PIXUVRI and any expansion of our sales and marketing organization for PIXUVRI; |
· |
regulatory approval developments; |
· |
ability to consummate appropriate collaborations for development and commercialization activities; |
· |
ability to reach milestones triggering payments under certain of our contractual arrangements, receive the associated payments and satisfy the conditions necessary to retain the funds from the June 2015 advance from Baxalta; |
· |
litigation and other disputes; |
· |
competitive market developments; and |
· |
other unplanned business developments. |
22
The following table includes information relating to our contractual obligations as of June 30, 2015 (in thousands):
Contractual Obligations |
|
Payments Due by Period |
|
|||||||||||||||||
|
|
Total |
|
|
Less than 1 Year |
|
|
1-3 Years |
|
|
3-5 Years |
|
|
More than 5 Years |
|
|||||
Operating leases: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facilities |
|
$ |
18,505 |
|
|
$ |
2,621 |
|
|
$ |
5,352 |
|
|
$ |
5,418 |
|
|
$ |
5,114 |
|
Long-term debt(1) (2) |
|
|
52,000 |
|
|
|
2,879 |
|
|
|
35,756 |
|
|
|
13,365 |
|
|